Contemporary Issues in Lung Cancer: A Nursing PerspectiveMarilyn Haas Jones and Bartlett Publishers, 2003 - 322 pages In the United States, lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer death. Even more devastating is its five-year survival rate of only 15.8%. Despite these dismal facts, lung cancer receives little national attention and research and funding for lung cancer lags behind other cancers. The intent of Contemporary Issues in Lung Cancer: A Nursing Perspective is to provide oncology nurses and healthcare professionals with in-depth information on the issues that surround this disease, so that they might impact both education and research and provide better care for their patients. Contemporary Issues in Lung Cancer addresses all aspects of the disease from incidence, risk factors, and the biology of lung cancer, to the latest modes of treatment. Also discussed are controversies in the detection and screening of lung cancer, and the special issues facing individuals with lung cancer. |
From inside the book
Results 1-3 of 35
Page 27
... initial evaluation of NSCLC . It does recognize the promising value it can add in pretreatment and post - treatment to follow up chest X - rays , CT , or MRI scans . Although PET scanning may not yet be recognized as the standard ...
... initial evaluation of NSCLC . It does recognize the promising value it can add in pretreatment and post - treatment to follow up chest X - rays , CT , or MRI scans . Although PET scanning may not yet be recognized as the standard ...
Page 229
... initial treatment phase quite well . She had a good initial understanding of the potential benefits and side effects of the investigational protocol she con- sented to . This included a combination of Carboplatin and Placitaxol with an ...
... initial treatment phase quite well . She had a good initial understanding of the potential benefits and side effects of the investigational protocol she con- sented to . This included a combination of Carboplatin and Placitaxol with an ...
Page 248
... initial starting dose is one spray to each nostril one to two times per hour on a regular basis . This dose may be supplemented by additional doses for a maximum daily dose of five doses per hour or 40 doses per day . The recommended ...
... initial starting dose is one spray to each nostril one to two times per hour on a regular basis . This dose may be supplemented by additional doses for a maximum daily dose of five doses per hour or 40 doses per day . The recommended ...
Contents
SEPARATING OUT THE DIFFERENCES BETWEEN LUNG | 3 |
BIOLOGY OF LUNG CANCER | 11 |
CHALLENGES OF CONDUCTING RESEARCH IN WOMEN WITH | 19 |
Copyright | |
20 other sections not shown
Other editions - View all
Common terms and phrases
abstr advanced non-small cell agents assessment associated behavior carboplatin cell carcinoma cell lung cancer chemotherapy chest cisplatin Clinical Oncology clinical trials combination decreased depression diagnosis disease docetaxel dose drug dyspnea etoposide evaluated factors fatigue gemcitabine healthcare impact improve increased individuals with lung intervention irinotecan Journal of Clinical lung cancer patients mediastinoscopy metastasis mg/m² multidisciplinary National Cancer Institute nicotine non-small cell lung Nursing Forum nutritional Oncol Oncology Nursing Oncology Nursing Forum paclitaxel pain palliative palliative care patients with advanced patients with lung Phase II study Phase II trial physical physician postoperative potential pulmonary radiation therapy radiotherapy radon measurements regimens resection response rates risk role SCLC Seminars in Oncology side effects sleep small cell lung smoking cessation Society of Clinical stage support groups surgery surgical symptom management Table thoracic thoracotomy tion tobacco topotecan treatment tumor vinorelbine weight loss